Apogenix GmbH is meeting officials from three of Europe’s leading national drug regulators in the coming weeks to evaluate whether they will support a bid to obtain conditional marketing approval for its glioblastoma drug APG101, following a fresh biomarker analysis, which shows that the therapy offers likely responders a 10-month survival benefit.